USC biomedical engineers have found a way to make a solid tumor paint a target on its own back in order to train the body's ...

Data demonstrates the significant and sustained tumor regression achieved by the CAPTN-3 platform across two distinct ...

Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor ...

Ragistomig is a 4-1BB X PD-L1 bispecific antibody, designed to treat patients with advanced or metastatic solid tumors, ...

Researchers from the Keck School of Medicine of USC have developed a new type of chimeric antigen receptor (CAR) T cell that ...

Automated TCR-T production streamlines personalized immunotherapy, reducing patient burden and improving engineered T cell quality.

Two years after this, Sakaguchi was able to link these discoveries. He proved that the Foxp3 gene governs the development of ...

A groundbreaking new treatment using genome-edited immune cells, developed by scientists at UCL (University College London) and Great Ormond Street Hospital (GOSH), has shown promising results in ...

Bispecific antibodies bring multiple tumor-cell-killing mechanisms into play simultaneously. When a T cell is activated and ...

CHICAGO — Rosnilimab, a novel pathogenic T-cell depleting drug, met its primary endpoint of changes in DAS28 C-reactive ...